1. Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999;40:407-414.
2. Miller R. Mechanism of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions. Curr Neuropharmacol. 2009;7:302-314.
3. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27-38.
4. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
5. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
6. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
7. Christian R, Saavedra L, Gaynes BN, et al. Future research needs for first- and second-generation antipsychotics for children and young adults [Internet]. Agency for Healthcare Research and Quality. 2012:12-EHC042-EF.
8. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359-1369.
9. Maglione M, Maher AR, Hu J, et al. Off-label use of atypical antipsychotics: An update [Internet]. Agency for Healthcare Research and Quality. 2011:11-EHC087-EF.
10. Ballard CG, Waite J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
11. Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367:1497-1507.
12. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev. 2008;(4):CD004844.
13. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26-36.
14. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5:26.
15. Ballon J, Stroup TS. Polypharmacy for schizophrenia. Curr Opin Psychiatry. 2013;26:208-213.
16. Krystal JH, Rosenheck RA, Cramer JA, et al; Veterans Affairs Cooperative Study No. 504 Group. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011;306:493-502.
17. Institute of Medicine. Retooling for an Aging America: Building the Health Care Workforce. Washington, DC: National Academy of Sciences; 2008.
18. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
19. Barrett E, Blonde L, Clement S, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
20. Drug Abuse Warning Network, 2010: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 12-4733, DAWN Series D-38. Substance Abuse and Mental Health Services Administration Web site. Available at: http://www.samhsa.gov/data/2k13/DAWN2k10ED/DAWN2k10ED.htm. Accessed May 1, 2013.
21. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
22. Pariente A, Fourrier-Réglat A, Ducruet T, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172:648-653.
23. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245.
24. Rossom RC, Rector TS, Lederle FA, et al. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc. 2010;58:1027-1034.
25. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169:71-79.
26. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012;344:e977.
27. US Food and Drug Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. US Food and Drug Administration Web site Available at: http://1.usa.gov/1plsxPk. Accessed February 5, 2014.
28. Information for healthcare professionals: conventional antipsychotics. US Food and Drug Administration Web site. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm. Accessed February 5, 2014.
29. Guide to the management of psychotic disorders and neuropsychiatric symptoms of dementia in older adults. American Geriatric Society Web site. Available at: http://dementia.americangeriatrics.org/GeriPsych_index.php. Accessed April 15, 2013.
30. Bogart GT, Ott CA. Abuse of second-generation antipsychotics: What prescribers need to know. Curr Psychiatr. 2011;10:77-79.
31. Tarosoff G, Osti K. Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada. Am J Psychiatry. 2007;164:350.
32. Highlights of the 2010 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality Web site. Available at: http://www.samhsa.gov/data/2k12/DAWN096/SR096EDHighlights2010.htm. Accessed May 1, 2013.
